[Intervention] for [health problem]

Characteristics of studies

Characteristics of included studies

Dawe 2005

Methods	**Study design:** Randomized controlled trial **Study grouping:** Parallel group **Open Label:** **Cluster RCT:**
Participants	**Baseline Characteristics** Intervention ● *Age*: ● *PASI Score (0-72) median (IQR)*: ● *Female %*: Control ● *Age*: ● *PASI Score (0-72) median (IQR)*: ● *Female %*: **Included criteria:** **Excluded criteria:** **Pretreatment:**
Interventions	**Intervention Characteristics** Intervention ● *Description*: ● *Length of treatment*: ● *Follow-up*: Control ● *Description*: ● *Length of treatment*: ● *Follow-up*:
Outcomes	*SEI* ● **Outcome type**: ContinuousOutcome ● **Measure names**: ["Baseline", "12 weeks"] ● **Reporting**: Fully reported ● **Scale**: SEI ● **Range**: 0-12 ● **Direction**: Lower is better ● **Data value**: Change from baseline ● **Notes**: Det er differenties for mean changes in SEI
Identification	**Sponsorship source:** **Country:** UK **Setting:** **Comments:** **Authors name:**

	Institution: **Email:** r.s.dawe@dundee.ac.uk **Address:**
Notes	*Birgitte Holm Petersen* on 13/08/2015 17:29 **Select** Til PICO 4 *Birgitte Holm Petersen* on 04/09/2015 21:52 **Study Design** Højre/venstre sammenligning *Birgitte Holm Petersen* on 04/09/2015 22:16 **Baseline Characteristics** ingen baseline data *Birgitte Holm Petersen* on 04/09/2015 22:37 **Continuous Outcomes** nummerisk data ej opgivet. Aflæst på graf. Kan ikke finde supplement, hvor der muligvis er data) Ingen signifikant forskel på grupperne. Follow-up 1 year. Ingen forskel på højre/ venstre.

Risk of bias table

Bias	Authors' judgement	Support for judgement
Blinding of participants and personnel klinisk effekt	Low risk	

Eysteinsdottir 2014

Methods	**Study design:** Randomized controlled trial **Study grouping:** Parallel group **Open Label:** YES **Cluster RCT:**
Participants	**Baseline Characteristics** Intervention ● *Age*: 41 ● *PASI Score (0-72) mean (IQR)*: 12.3 ● *Female %*: 45 Control ● *Age*: 41 ● *PASI Score (0-72) mean (IQR)*: 12.3 ● *Female %*: 45 Intervention 2 ● *Age*: 41 ● *PASI Score (0-72) mean (IQR)*: 12.3 ● *Female %*: 45

	Included criteria: (a) diagnosis ofchronic plaque psoriasis; (b) Psoriasis Area and SeverityIndex (PASI) score (20)of7or higher; and (c) being unre-sponsive to topical treatment and being a candidate forphototherapy or systemic treatment. **Excluded criteria:** Patients with otherforms of psoriasis (e.g. guttate, pustular or erythrodermic)or skin diseases that could interfere with study evaluationswere excluded. **Pretreatment:** Intervention 2 had a significant higter DLQI score at baseline compared to the other groups
Interventions	**Intervention Characteristics** Intervention ● *Description*: Bathing in geothermal seawater for1h and NB-UVB therapy immediately afterwards three times a week ● *Length of treatment*: 6 weeks (follow by nUBV in 4 weeks for 6/22 patient) ● *Follow-up*: 1,2,4,6,10 weeks Control ● *Description*: UVB 6 weeks ● *Length of treatment*: 6 weeks (10 weeks for 16/24 patient) ● *Follow-up*: 1,2,4,6,10 weeks Intervention 2 ● *Description*: bathing in geothermal seawater for1h two times a day and NB-UVB therapy once daily immediately after the first bath six times/week for 2 weeks follow by 4 weeks of´nUVB ● *Length of treatment*: 6 weeks (follow by nUBV in 4 weeks for 6/22 patient) ● *Follow-up*: 1,2,4,6,10 weeks
Outcomes	*PASI-75* ● **Outcome type**: DichotomousOutcome ● **Measure names**: ["Baseline", "4-6 weeks", "10 weeks"] ● **Reporting**: Fully reported ● **Direction**: Higher is better ● **Data value**: Change from baseline ● **Notes**: week 6 *PASI-90* ● **Outcome type**: DichotomousOutcome ● **Measure names**: ["Baseline", "4-6 weeks", "10 weeks"] ● **Reporting**: Fully reported ● **Direction**: Higher is better ● **Data value**: Change from baseline ● **Notes**: Week 10 *DLQI <2 end of treatment* ● **Outcome type**: DichotomousOutcome ● **Measure names**: ["Baseline", "4-6 weeks", "10 weeks"] ● **Direction**: Higher is better ● **Data value**: Change from baseline *Skincancer (end of treatment)* ● **Outcome type**: DichotomousOutcome ● **Measure names**: ["Baseline", "4-6 weeks", "10 weeks"] ● **Reporting**: Not reported

	PASI reduktion mininum 12 uger efter end behandling ● **Outcome type**: DichotomousOutcome ● **Measure names**: ["Baseline", "4-6 weeks", "10 weeks"] ● **Reporting**: Not reported ● **Direction**: Higher is better ● **Data value**: Change from baseline
Identification	**Sponsorship source:** The Blue Lagoon Ltd and Icelandic Technology Development Fund and the Landspitali University Hospital Research Fund **Country:** Iceland **Setting:** **Comments:** **Authors name:** Jenna Huld Eysteinsdóttir **Institution:** Faculty of Medicine, Universityof Iceland, Reykjavík, Iceland **Email:** jennahuld@gmail.com **Address:** Department of Dermatology, Sahlgrenska University Hospital, Gröna Stråket16, Göteborg 413 45, Sweden.
Notes	*Birgitte Holm Petersen* on 13/08/2015 17:43 **Select** Til PICO 4 *Birgitte Holm Petersen* on 28/08/2015 23:26 **Continuous Outcomes** Skriver ikke hvad deres +/- værdier er, men i baseline tabel bruges mean +/-SD, så går ud fra at dette bruges hele vejen igennem *Jakob Torp Madsen* on 09/09/2015 18:51 **Adverse Outcomes** 1 polymorphic light eruption and then excluded

Risk of bias table

Bias	Authors' judgement	Support for judgement
Blinding of participants and personnel All outcomes	Unclear risk	
Blinding of participants and personnel Klinisk effekt	High risk	Judgement Comment: Umuligt at blinde forsøgsdeltagere
Incomplete outcome data Livskvalitet	Unclear risk	
Incomplete outcome data Klinisk effekt	Low risk	
Blinding of outcome assessors Klinisk effekt	Unclear risk	Judgement Comment: Ikke klart om lægen er blindet.

Klein 2011

Methods	**Study design:** Randomized controlled trial **Study grouping:** Parallel group **Open Label:** **Cluster RCT:**
Participants	**Baseline Characteristics** Intervention ● *Age*: 45 ● *PASI Score (0-72) median (IQR)*: 15.1 ● *Female %*: 44 Control ● *Age*: 45 ● *PASI Score (0-72) median (IQR)*: 15.1 ● *Female %*: 44 **Included criteria:** **Excluded criteria:** **Pretreatment:**
Interventions	**Intervention Characteristics** Intervention ● *Description*: ● *Length of treatment*: ● *Follow-up*: Control ● *Description*: ● *Length of treatment*: ● *Follow-up*:
Outcomes	*SEI* ● **Outcome type**: ContinuousOutcome ● **Measure names**: ["Baseline", "12 weeks/End of treatment ", "1 month follow up ", "6 month follow up"] *PASI (MEDIAN VALUE)* ● **Outcome type**: ContinuousOutcome ● **Measure names**: ["Baseline", "12 weeks/End of treatment ", "1 month follow up ", "6 month follow up"] ● **Reporting**: Fully reported ● **Scale**: PASI ● **Range**: 0-72 ● **Direction**: Lower is better ● **Data value**: Change from baseline
Identification	**Sponsorship source:** **Country:** **Setting:** **Comments:** **Authors name:** **Institution:** Department of Dermatology, University Hospital Regensburg,

	Regensburg, and‡Department of Dermatology, KlinikumMu¨nchen-Schwabing, Munich, Germany **Email:** annette.klein@klinik.uni-regensburg.de **Address:**
Notes	*Birgitte Holm Petersen* on 13/08/2015 18:54 **Select** Til PICO 4 *Jakob Torp Madsen* on 09/09/2015 22:30 **Continuous Outcomes** Kan ikke finde standard deviationer.

Risk of bias table

Bias	Authors' judgement	Support for judgement
Blinding of participants and personnel All outcomes	High risk	

Leaute Labreze 2001

Methods	**Study design:** Randomized controlled trial **Study grouping:** Parallel group **Open Label:** **Cluster RCT:**
Participants	**Baseline Characteristics** Intervention ● *Age*: 48.5 ● *PASI Score (0-72) median (IQR)*: 15.7 ● *Female %*: Control ● *Age*: 48.5 ● *PASI Score (0-72) median (IQR)*: 15.7 ● *Female %*: **Included criteria:** **Excluded criteria:** **Pretreatment:**
Interventions	**Intervention Characteristics** Intervention ● *Description*: ● *Length of treatment*: ● *Follow-up*: Control ● *Description*: ● *Length of treatment*: ● *Follow-up*:

Outcomes	*SEI* ● **Outcome type**: ContinuousOutcome ● **Measure names**: ["Baseline", "12 weeks", "21 days/end of treatment ", "1 year follow up "] *Gruppens samlede ændringer i PASI i %* ● **Outcome type**: ContinuousOutcome ● **Measure names**: ["Baseline", "12 weeks", "21 days/end of treatment ", "1 year follow up "] ● **Scale**: % ● **Range**: -100-0% ● **Direction**: Higher is better ● **Data value**: Change from baseline *Quality of life index* ● **Outcome type**: ContinuousOutcome ● **Measure names**: ["Baseline", "12 weeks", "21 days/end of treatment ", "1 year follow up "] ● **Scale**: 0-10 ● **Range**: -100-100% ● **Data value**: Change from baseline ● **Notes**: change in quality-of-life index determined ona 10-cm analog scale, KAn ikke finde oplysinger på hvad den er og kan ikke finde den relevante reference.
Identification	**Sponsorship source:** **Country:** France **Setting:** **Comments:** **Authors name:** **Institution:** **Email:** **Address:**
Notes	*Birgitte Holm Petersen* on 13/08/2015 18:58 **Select** PICO 4 *Jakob Torp Madsen* on 09/09/2015 20:04 **Baseline Characteristics** Kønsratioen er kun bestemt for hele gruppen ved baseline, men kan ikke extraheres til de enkelte grupper

Risk of bias table

Bias	Authors' judgement	Support for judgement
Blinding of participants and personnel All outcomes	High risk	
Sequence Generation		

Incomplete outcome data All outcomes	High risk	
Other sources of bias	Low risk	
Selective outcome reporting	Low risk	
Allocation concealment	Unclear risk	
Blinding of outcome assessors All outcomes	Unclear risk	

Olafsson 1996

Methods	**Study design:** **Study grouping:** Parallel group **Open Label:** YES **Cluster RCT:**
Participants	**Baseline Characteristics** Intervention ● *Age*: ● *PASI Score (0-72) median (IQR)*: ● *Female %*: 43 Control ● *Age*: ● *PASI Score (0-72) median (IQR)*: ● *Female %*: 43 **Included criteria:** **Excluded criteria:** **Pretreatment:**
Interventions	**Intervention Characteristics** Intervention ● *Description*: ● *Length of treatment*: 4 weeks ● *Follow-up*: Control ● *Description*: ● *Length of treatment*: 4 weeks ● *Follow-up*:
Outcomes	*SEI* ● **Outcome type**: ContinuousOutcome ● **Measure names**: ["Baseline", "12 weeks"] *PASI* ● **Outcome type**: ContinuousOutcome ● **Measure names**: ["Baseline", "12 weeks"] ● **Reporting**: Fully reported ● **Scale**: PASI ● **Range**: 0-72 ● **Direction**: Lower is better

	● **Data value**: Change from baseline *PASI* ● **Outcome type**: ContinuousOutcome ● **Measure names**: ["Baseline", "4 weeks /end of treatment "] ● **Reporting**: Fully reported ● **Scale**: PASI ● **Range**: 0-72 ● **Direction**: Lower is better ● **Data value**: Change from baseline *PASI75 reduktion* ● **Outcome type**: DichotomousOutcome ● **Measure names**: ["Baseline"] ● **Scale**: % PASI reduktion ● **Range**: 100-0 ● **Direction**: Higher is better ● **Data value**: Endpoint
Identification	**Sponsorship source:** **Country:** **Setting:** **Comments:** **Authors name:** **Institution:** **Email:** **Address:**
Notes	*Birgitte Holm Petersen* on 13/08/2015 19:07 **Select** PICO 4

Risk of bias table

Bias	Authors' judgement	Support for judgement
Sequence Generation	High risk	Judgement Comment: ej randomiseret
Incomplete outcome data All outcomes	High risk	Judgement Comment: ej beregnet SD, Se eller 95% Ci interval på PASI

Footnotes

Characteristics of excluded studies

Avrach 1974

Reason for exclusion	Wrong study design

Baros 2014

Reason for exclusion	Wrong comparator

Ben Amitai 2009

Reason for exclusion	Wrong study design

Boer 1996

Reason for exclusion	Wrong study design

Boreham 1995

Reason for exclusion	Wrong study design

Borroni 2013

Reason for exclusion	Wrong intervention

Brockow 2007

Reason for exclusion	Wrong comparator

Brockow 2007a

Reason for exclusion	Wrong comparator

Cattaneo 2012

Reason for exclusion	Wrong study design

Cohen 2005

Reason for exclusion	Wrong study design

Even Paz 1996

Reason for exclusion	Wrong comparator

GalvezGalve 2012

Reason for exclusion	Wrong intervention

Gambichler 2000

Reason for exclusion	Wrong study design

Gambichler 2001

Reason for exclusion	Wrong intervention

Gambichler 2006

Reason for exclusion	Wrong study design

Halevy 1997

Reason for exclusion	Wrong intervention

Harari 2007

Reason for exclusion	Wrong study design

Mork 2004

Reason for exclusion	Wrong study design

Morri 2012

Reason for exclusion	Wrong comparator

Olafsson 1994

Reason for exclusion	Wrong study design

Olafsson 1996a

Reason for exclusion	Wrong study design

Ozcelik 2000

Reason for exclusion	Wrong intervention

Peroni 2008

Reason for exclusion	Wrong comparator

Pinton 1995

Reason for exclusion	Wrong study design

Schewach Millet 1989

Reason for exclusion	Wrong study design

Schiener 2006

Reason for exclusion	Wrong intervention

Schiener 2007

Reason for exclusion	Wrong comparator

Schiffner 2000

Reason for exclusion	Wrong study design

Snellman 1992

Reason for exclusion	Wrong study design

Snellman 1993

Reason for exclusion	Wrong study design

Snellman 1993a

Reason for exclusion	Wrong study design

Snellman 1998

Reason for exclusion	Wrong outcomes

Sukenik 1997

Reason for exclusion	Wrong study design

Trueb 2009

Reason for exclusion	Wrong study design

Ubogui 1998

Reason for exclusion	Wrong intervention

Verdolini 2005

Reason for exclusion	Wrong intervention

Footnotes

Characteristics of studies awaiting classification

Footnotes

Characteristics of ongoing studies

Footnotes

Summary of findings tables

Additional tables

References to studies

Included studies

Dawe 2005

Dawe,R. S.; Yule,S.; Cameron,H.; Moseley,H.; Ibbotson,S. H.; Ferguson,J.. A randomized controlled comparison of the efficacy of Dead Sea salt balneophototherapy vs. narrowband ultraviolet B monotherapy for chronic plaque psoriasis.. British Journal of Dermatology 2005;153(3):613-619. [DOI: http://dx.doi.org/10.1111/j.1365-2133.2005.06663.x]

Eysteinsdottir 2014

Eysteinsdottir,J. H.; Olafsson,J. H.; Agnarsson,B. A.; Ludviksson,B. R.; Sigurgeirsson,B.. Psoriasis treatment: Faster and long-standing results after bathing in geothermal seawater. A randomized trial of three UVB phototherapy regimens.. Photodermatology Photoimmunology and Photomedicine 2014;30(1):25-34. [DOI: http://dx.doi.org/10.1111/phpp.12090]

Klein 2011

Klein,A.; Schiffner,R.; Schiffner-Rohe,J.; Einsele-Kramer,B.; Heinlin,J.; Stolz,W.; Landthaler,M.. A randomized clinical trial in psoriasis: Synchronous balneophototherapy with bathing in Dead Sea salt solution plus narrowband UVB vs. narrowband UVB alone (TOMESA-study group).. Journal of the European Academy of Dermatology and Venereology 2011;25(5):570-578. [DOI: http://dx.doi.org/10.1111/j.1468-3083.2010.03840.x]

Leaute Labreze 2001

Leaute-Labreze,C.; Saillour,F.; Chene,G.; Cazenave,C.; Luxey-Bellocq,M. -L; Sanciaume,C.; Toussaint,J. F.; Taieb,A.. Saline spa water or combined water and UV-B for psoriasis vs conventional UV-B: Lessons from the Salies de Bearn randomized study.. Archives of Dermatology 2001;137(8):1035-1039. [DOI:]

Olafsson 1996

Olafsson,J. H.; Sigurgeirsson,B.; Palsdottir,R.. Psoriasis treatment: Bathing in a thermal lagoon combined with UVB, versus UVB treatment only.. Acta Dermato-Venereologica 1996;76(3):228-230. [DOI:]

Excluded studies

Avrach 1974

Avrach,W. W.; Niordsen,A. M.. Treatment of psoriasis at the Dead Sea (Danish).. Ugeskrift for laeger 1974;136(48):2687-2690. [DOI:]

Baros 2014

Baros DN; Gajanin VS; Gajanin RB; Zrnic B. Comparative analysis of success of psoriasis treatment with standard therapeutic modalities and balneotherapy.. Medicinski pregled 2014;67(5-6):154-160. [DOI:]

Ben Amitai 2009

Ben-Amitai D; David M. Climatotherapy at the dead sea for pediatric-onset psoriasis vulgaris.. Pediatric dermatology 2009;26(1):103-104. [DOI: http://dx.doi.org/10.1111/j.1525-1470.2008.00837.x]

Boer 1996

Boer,J.. The influence of mineral water solutions in phototherapy. Clinics in dermatology 1996;14(6):665-673. [DOI:]

Boreham 1995

Boreham,D. R.; Gasmann,H. C.; Mitchel,R. E. J.. Water bath hyperthermia is a simple therapy for psoriasis and also stimulates skin tanning in response to sunlight.. International Journal of Hyperthermia 1995;11(6):745-754. [DOI:]

Borroni 2013

Borroni,G.; Brazzelli,V.; Fornara,L.; Rosso,R.; Paulli,M.; Tinelli,C.; Ciocca,O.. Clinical, pathological and immunohistochemical effects of arsenical-ferruginous spa waters on mild-to-moderate psoriatic lesions: A randomized placebo-controlled study.. International Journal of Immunopathology and Pharmacology 2013;26 (2):495-501. [DOI:]

Brockow 2007

Brockow,T.; Schiener,R.; Franke,A.; Resch,K. L.; Peter,R. U.. A pragmatic randomized controlled trial on the effectiveness of low concentrated saline spa water baths followed by ultraviolet B (UVB) compared to UVB only in moderate to severe psoriasis.. Journal of the European Academy of Dermatology and Venereology 2007;21 (8):1027-1037. [DOI: http://dx.doi.org/10.1111/j.1468-3083.2007.02152.x]

Brockow 2007a

Brockow, T.; Schiener, R.; Franke, A.; Resch, K. L.; Peter, R. U.. A pragmatic randomized controlled trial on the effectiveness of highly concentrated saline spa water baths followed by UVB compared to UVB only in moderate to severe psoriasis. 2007;13(7):725-732. [DOI: 10.1089/acm.2007.7099]

Cattaneo 2012

Cattaneo,A.; Alberti Violetti,S.; Tavecchio,S.; Bruni,E.; Carrera,C.; Crosti,C.. Tomesa balneophototherapy in mild to severe psoriasis: A retrospective clinical trial in 174 patients.. Photodermatology Photoimmunology and Photomedicine 2012;28(3):169-171. [DOI: http://dx.doi.org/10.1111/j.1600-0781.2012.00659.x]

Cohen 2005

Cohen AD; Van-Dijk D; Naggan L; Vardy DA. Effectiveness of climatotherapy at the Dead Sea for psoriasis vulgaris: A community-oriented study introducing the 'Beer Sheva Psoriasis Severity Score'.. Journal of Dermatological Treatment 2005;16(5-6):308-313. [DOI:]

Even Paz 1996

Even-Paz,Z.; Gumon,R.; Kipnis,V.; Abels,D. J.; Efron,D.. Dead Sea sun versus Dead Sea water in the treatment of psoriasis.. Journal of Dermatological Treatment 1996;7(2):83-86. [DOI:]

GalvezGalve 2012

Galvez Galve, J. J.; Peiro, P. S.; Lucas, M. O.; Torres, A. H.; Gil, E. S.; Perez, M. B.. Quality of life and assessment after local application of sulphurous water in the home environment in patients with psoriasis vulgaris: A randomised placebo-controlled pilot study. European Journal of Integrative Medicine 2012;4(2): e213-e218. [DOI: http://dx.doi.org/10.1016/j.eujim.2012.01.001]

Gambichler 2000

Gambichler,T.; Kuster,W.; Kreuter,A.; Altmeyer,P.; Hoffmann,K.. Balneophototherapy - Combined treatment of psoriasis vulgaris and atopic dermatitis with salt water baths and artificial ultraviolet radiation [4].. Journal of the European Academy of Dermatology and Venereology 2000;14(5):425-428. [DOI: http://dx.doi.org/10.1046/j.1468-3083.2000.00102-4.x]

Gambichler 2001

Gambichler,T.; Rapp,S.; Senger,E.; Altmeyer,P.; Hoffmann,K.. Balneophototherapy of psoriasis: Highly concentrated salt water versus tap water - A randomized, one-blind, right/left comparative study.. Photodermatology Photoimmunology and Photomedicine 2001;17(1):22-25. [DOI: http://dx.doi.org/10.1034/j.1600-0781.2001.017001022.x]

Gambichler 2006

Gambichler,T.; Tomi,N. S.; Kreuter,A.. Controlled clinical trials on balneophototherapy in psoriasis [18].. British Journal of Dermatology 2006;154(4):802-803. [DOI: http://dx.doi.org/10.1111/j.1365-2133.2006.07176.x]

Halevy 1997

Halevy,S.; Giryes,H.; Friger,M.; Sukenik,S.. Dead sea bath salt for the treatment of psoriasis vulgaris: A double- blind controlled study.. Journal of the European Academy of Dermatology and Venereology 1997;9(3): 237-242. [DOI: http://dx.doi.org/10.1016/S0926-9959%2897%2900133-5]

Harari 2007

Harari M; Novack L; Barth J; David M; Friger M; Moses SW. The percentage of patients achieving PASI 75 after 1 month and remission time after climatotherapy at the Dead Sea.. International journal of dermatology 2007;46 (10):1087-1091. [DOI:]

Mork 2004

Mork C; Ozek M; Wahl AK. [Psoriasis and psoriatic arthritis--is climate therapy a treatment or a leisure activity?]. Tidsskrift for den Norske laegeforening 2004;124(1):60-62. [DOI:]

Morri 2012

Morri,M.; Norat,M.; Canzi,P.; Viti,S.; Mascherpa,M. A.; Angeli,P.; Angeli,F.; Romani,G.. Balneotherapy and narrow-band phototherapy in the treatment of psoriasis: A comparative study.. Gazzetta Medica Italiana Archivio per le Scienze Mediche 2012;171(6):739-748. [DOI:]

Olafsson 1994

Olafsson,J. H.; Sigurgeirsson,B.; Palsdottir,R.. The effect bathing in a thermal lagoon in Iceland has on psoriasis. A preliminary study.. Journal of the European Academy of Dermatology and Venereology 1994;3(4): 460-464. [DOI:]

Olafsson 1996a

Olafsson,J. H.. The Blue Lagoon in Iceland and psoriasis. Clinics in dermatology 1996;14(6):647-651. [DOI:]

Ozcelik 2000

Ozcelik S; Polat HH; Akyol M; Yalcin AN; Ozcelik D; Marufihah M. Kangal hot spring with fish and psoriasis treatment.. Journal of Dermatology 2000;27(6):386-390. [DOI:]

Peroni 2008

Peroni,A.; Gisondi,P.; Zanoni,M.; Girolomoni,G.. Balneotherapy for chronic plaque psoriasis at Comano spa in Trentino, Italy.. Dermatologic Therapy 2008;21(SUPPL. 1):S31-S38. [DOI: http://dx.doi.org/10.1111/j.1529-8019.2008.00200.x]

Pinton 1995

Pinton,J.; Friden,H.; Kettaneh-Wold,N.; Wold,S.; Dreno,B.; Richard,A.; Bieber,T.. Clinical and biological effects of balneotherapy with selenium-rich spa water in patients with psoriasis vulgaris [13].. British Journal of Dermatology 1995;133(2):344-347. [DOI: http://dx.doi.org/10.1111/j.1365-2133.1995.tb02657.x]

Schewach Millet 1989

Schewach-Millet M; Feinstein A; Trau H; Abel EA; Cox AJ. Histologic studies in psoriatic patients treated at the Dead Sea: comparison with photochemotherapy.. Journal of the American Academy of Dermatology 1989;20 (3):502-503. [DOI:]

Schiener 2006

Schiener,A.; Brockow,T.; Weimer,M.; Hochdorfer,B.; Freitag,L.; Salzer,B.; Resch,E.; Peter,R. U.. Balneo-phototherapy. Superiority can no longer be denied.. Journal of Plastic Dermatology 2006;2(2):39-41. [DOI:]

Schiener 2007

Schiener R; Brockow T; Franke A; Salzer B; Peter RU; Resch KL. Bath PUVA and saltwater baths followed by UV-B phototherapy as treatments for psoriasis: a randomized controlled trial.. Archives of Dermatology 2007; 143(5):586-596. [DOI:]

Schiffner 2000

Schiffner,R.; Schiffner-Rohe,J.; Wolfl,G.; Landthaler,M.; Glalssl,A.; Walther,Th; Hofstadter,F.; Stolz,W.. Evaluation of a multicentre study of synchronous application of narrowband ultraviolet B phototherapy (TL-01) and bathing in Dead Sea salt solution for psoriasis vulgaris.. British Journal of Dermatology 2000;142(4):740-747. [DOI: http://dx.doi.org/10.1046/j.1365-2133.2000.03420.x]

Snellman 1992

Snellman,E.. Comparison of the antipsoriatic efficacy of heliotherapy and ultraviolet B: a cross-over study.. Photodermatology, photoimmunology & photomedicine 1992;9(2):83-85. [DOI:]

Snellman 1993

Snellman,E.; Aromaa,A.; Jansen,C. T.; Lauharanta,J. A.; Reunanen,A.; Jyrkinen-Pakkasvirta,T.; Luoma,J.; Waal,J.. Supervised four-week heliotherapy alleviates the long-term course of psoriasis.. Acta Dermato-Venereologica 1993;73(5):388-392. [DOI:]

Snellman 1993a

Snellman,E.; Lauharanta,J.; Reunanen,A.; Jansen,C. T.; Jyrkinen-Pakkasvirta,T.; Kallio,M.; Luoma,J.; Aromaa, A.; Waal,J.. Effect of heliotherapy on skin and joint symptoms in psoriasis: A 6-month follow-up study.. British Journal of Dermatology 1993;128(2):172-177. [DOI: http://dx.doi.org/10.1111/j.1365-2133.1993.tb15147.x]

Snellman 1998

Snellman,E.; Maljanen,T.; Aromaa,A.; Reunanen,A.; Jyrkinen-Pakkasvirta,T.; Luoma,J.. Effect of heliotherapy on the cost of psoriasis.. British Journal of Dermatology 1998;138(2):288-292. [DOI: http://dx.doi.org/10.1046/j.1365-2133.1998.02076.x]

Sukenik 1997

Sukenik S; Abu-Shakra M; Flusser D. Balneotherapy in autoimmune disease. Israel journal of medical sciences 1997;33(4):258-261. [DOI:]

Trueb 2009

Trueb,R. M.. Therapies for childhood psoriasis. Current problems in dermatology 2009;38(Journal Article):137-159. [DOI: http://dx.doi.org/10.1159/000232308]

Ubogui 1998

Ubogui J; Stengel FM; Kien MC; Sevinsky L; Rodriguez Lupo L. Thermalism in Argentina. Alternative or complementary dermatologic therapy.. Archives of Dermatology 1998;134(11):1411-1412. [DOI:]

Verdolini 2005

Verdolini,R.; Bugatti,L.; Filosa,G.; Mannello,B.; Lawlor,F.; Cerio,R. R.. Old fashioned sodium bicarbonate baths for the treatment of psoriasis in the era of futuristic biologics: An old ally to be rescued.. Journal of Dermatological Treatment 2005;16(1):26-30. [DOI: http://dx.doi.org/10.1080/09546630410024862]

Studies awaiting classification

Ongoing studies

Other references

Additional references

Other published versions of this review

Data and analyses

3 Control vs Intervention 2

Outcome or Subgroup	Studies	Participants	Statistical Method	Effect Estimate
3.6 PASI75	2	84	Risk Ratio (M-H, Random, 95% CI)	0.25 [0.13, 0.46]
3.7 PASI score end of treatment	1	356	Mean Difference (IV, Fixed, 95% CI)	6.40 [4.60, 8.20]

3.8 PASI score 6 mdr. follow-up	1	273	Mean Difference (IV, Fixed, 95% CI)	2.20 [0.79, 3.61]

Figures

Figure 1 (Analysis 3.8)



Forest plot of comparison: 3 Control vs Intervention 2, outcome: 3.8 PASI score 6 mdr. follow-up.

Figure 2 (Analysis 3.7)



Forest plot of comparison: 3 Control vs Intervention 2, outcome: 3.7 PASI score end of treatment.

Figure 3 (Analysis 3.6)



Forest plot of comparison: 3 Control vs Intervention 2, outcome: 3.6 PASI75.

Appendices